By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Bayer HealthCare LLC v. Abbott Laboratories et al.
6:08-cv-00507; filed December 24, 2008 in the Eastern District of Texas
Infringement of U.S. Patent No. 5,654,407 ("Human Anti-TNF Antibodies," issued August 5, 1997) based on Abbott's manufacture and sale of its Humira ® (adalimumab, used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and plaque psoriasis). View the complaint here.
Eli Lilly and Company v. Lupin Pharmaceuticals, Inc. et al.
3:08-cv-06261; filed December 22, 2008 in the District Court of New Jersey
Eli Lilly and Company v. Sun Pharmaceutical Industries, Inc. et al.
3:08-cv-06266; filed December 22, 2008 in the District Court of New Jersey
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 5,023,269 ("3-Aryloxy-3-Substituted Propanamines," issued June 11, 1991) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Lilly's Cymbalta® (duloxetine hydrochloride, used to treat depression and generalized anxiety disorder and for the management of diabetic peripheral neuropathic pain and fibromyalgia). View the Lupin complaint here.
Sanofi-Aventis U.S. LLC et al. v. Ebewe Pharma GES.M.B.H. NFG.KG
3:08-cv-06243; filed December 19, 2008 in the District Court of New Jersey
Infringement of U.S. Patent No. 5,338,874 ("Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) Having Optically High Purity," issued August 16, 1994) following a Paragraph IV certification as part of Ebewe's filing of an ANDA to manufacture a generic version of plaintiffs' Eloxatin® (oxaliplatin for injection, used to treat colorectal cancer). View the complaint here.
Novartis Corp. et al. v. Teva Parenteral Medicines Inc. et al.
1:08-cv-00952; filed December 18, 2008 in the District Court of Delaware
Infringement of U.S. Patent No. 4,939,130 ("Substituted Alkanediphosphonic Acids and Pharmaceutical Use," issued July 3, 1990) following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Novartis' Reclast® (zoledronic acid injection, once-yearly treatment for postmenopausal osteoporosis). View the complaint here.
Novartis Corp. et al. v. Cobalt Laboratories, Inc. et al.
2:08-cv-06223; filed December 18, 2008 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,162,802 ("Synergistic Combination Therapy Using Benazepril and Amlodipine for the Treatment of Cardiovascular Disorders and Compositions Therefor," issued December 19, 2000) following a Paragraph IV certification as part of Cobalt's filing of an ANDA to manufacture a generic version of Novartis' Lotrel® (amlodipine besylate/benazepril hydrochloride, used to treat hypertension). View the complaint here. [As previously reported in Court Report, Novartis filed suit against Cobalt earlier this year on this same patent based on an ANDA directed to different dosage forms.]
Comments